Ziresovir TQT Study Initiated by Shanghai Ark Biopharma
A TQT clinical study evaluating ziresovir's effects on cardiac repolarization has been initiated.
Asset / Drug
Drug and asset intelligence for ziresovir with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.